IP Library Granted Patent US 7,997,279
Granted Patent B2
US 7,997,279 · App. 12/264,112 · Granted Aug 16, 2011

Methods for treating eye conditions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,997,279
App. No.
12/264,112
Granted
Aug 16, 2011
Kind
B2
Abstract

Architectures and techniques for treating conditions of the eye, such as presbyopia, utilize sources of treatment energy, such as electromagnetic energy emitting devices, to implement non-corneal manipulations. According to these devices and methods, the sources of treatment energy are activated to direct energy onto parts of the eye, such as the conjunctiva and sclera, to treat presbyopia. The treatments can affect at least one property of the eye and enhance an accommodation of the eye.

Claims (26)

1. A method for treating a patient ocular site in need of one or more of a physiological and a vision or perceptual correction, comprising directing treatment energy to and through a first intercepting tissue and to and within a second intercepting tissue of the biological site, an intersection of the treatment energy and the first intercepting tissue having a first shape and a first area, and an intersection of the treatment energy and the second intercepting tissue having a second reference shape and a second reference area, wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the first shape is greater than a maximum dimension of the first reference shape, (b) the first area is greater than the first reference area, and (c) a maximum concentration or intensity of treatment energy in the first area is less than a maximum concentration or intensity of treatment energy in the first reference area.

2. The method as set forth in claim 1 , wherein a characteristic or measurable parameter of the treatment energy tapers within the first intercepting tissue from about 1 or more percent with each 1 percent drop in depth within the first intercepting tissue.

3. The method as set forth in claim 2 , wherein:

the first intercepting tissue is a conjunctiva;

the second intercepting tissue is a sclera; and

the characteristic or measurable parameter is a diameter of the treatment energy.

4. The method as set forth in claim 1 , wherein a profile of the treatment energy has one or more of a conical and a “V” shape.

5. The method as set forth in claim 1 , wherein the directing is characterized by (a) a maximum dimension of the first shape being greater than a maximum dimension of the first reference shape.

6. The method as set forth in claim 5 , wherein the directing is further characterized by (b) the first area being greater than the first reference area.

7. The method as set forth in claim 6 , wherein the directing is further characterized by (c) a maximum concentration or intensity of treatment energy in the first area being less than a maximum concentration or intensity of treatment energy in the first reference area.

8. The method as set forth in claim 1 , wherein the directing is characterized by (b) the first area being greater than the first reference area.

9. The method as set forth in claim 8 , wherein the directing is further characterized by (c) the maximum concentration or intensity of treatment energy in the first area being less than a maximum concentration or intensity of treatment energy in the first reference area.

10. The method as set forth in claim 1 , wherein the directing is characterized by (c) a maximum concentration or intensity of treatment energy in the first area being less than a maximum concentration or intensity of treatment energy in the first reference area.

11. The method as set forth in claim 10 , wherein the directing is further characterized by (a) a maximum dimension of the first shape being greater than a maximum dimension of the first reference shape.

12. A method for treating a patient ocular or other or related tissue site in need of one or more of a physiological and a vision or perceptual correction, comprising directing treatment energy to and through a first intercepting tissue and to and within a second intercepting tissue of the biological site, an intersection of the treatment energy and the first intercepting tissue having a first shape and a first area, and an intersection of the treatment energy and the second intercepting tissue having a second reference shape and a second reference area, wherein the directing is characterized by a plurality of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the first shape is greater than a maximum dimension of the first reference shape, (b) the first area is greater than the first reference area, and (c) a maximum concentration or intensity of treatment energy in the first area is less than a maximum concentration or intensity of treatment energy in the first reference area.

13. The method as set forth in claim 12 , wherein the treatment energy has a focal point, which is on or in the second intercepting tissue.

14. The method as set forth in claim 12 , wherein:

the first intercepting tissue is a conjunctiva;

the second intercepting tissue is a sclera; and

the treatment energy is focused on or into the second intercepting tissue more so than on the first intercepting tissue.

15. The method as set forth in claim 12 , wherein the treatment energy is focused on or into the second intercepting tissue to an extent, which is greater than an extent to which the treatment energy is focused on or into the first intercepting tissue.

16. The method as set forth in claim 12 , wherein treatment energy is focused on or inside the second intercepting tissue rather than on the first intercepting tissue.

17. The method as set forth in claim 12 , wherein portions of the first intercepting tissue penetrated by the treatment energy are not substantially ablated by the treatment energy.

18. The method as set forth in claim 12 , wherein portions of the first intercepting tissue penetrated by the treatment energy are affected to a lesser extent than the extent to which the second intercepting tissue is affected by the treatment energy.

19. The method as set forth in claim 12 , wherein the treatment energy comprises a first beam of treatment energy and the method further comprises directing a second beam of treatment energy through the first intercepting tissue and to a second intercepting tissue, wherein an intersection of the second beam and the first intercepting tissue has a second shape and a second area, an intersection of the second beam and the second intercepting tissue having a second reference shape and a second reference area, and wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the second shape is greater than a maximum dimension of the second reference shape, (b) the second area is greater than the second reference area, and (c) a maximum concentration or intensity of treatment energy in the second area is less than a maximum concentration or intensity of treatment energy in the second reference area.

20. The method as set forth in claim 12 , wherein the method further comprises directing a third beam of treatment energy through the first intercepting tissue and onto a second intercepting tissue, wherein an intersection of the third beam and the first intercepting tissue has a third shape and a third area, an intersection of the third beam and the second intercepting tissue having a third reference shape and a third reference area, and wherein the directing is characterized by one or more of the following non-equivalent and non-interchangeable features: (a) a maximum dimension of the third shape is greater than a maximum dimension of the third reference shape, (b) the third area is greater than the third reference area, and (c) a maximum concentration or intensity of treatment energy in the third area is less than a maximum concentration or intensity of treatment energy in the third reference area.

Assignments (11)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 17, 2024
From: BIOLASE, INC.; BL ACQUISITION CORP.; BL ACQUISITION II, INC.
To: BIOLASE MG LLC
Reel/Frame 069715/0613 →
SECURITY INTEREST Recorded Oct 30, 2019
From: BIOLASE, INC.
To: PACIFIC MERCANTILE BANK
Reel/Frame 050879/0223 →
SECURITY INTEREST Recorded Nov 16, 2018
From: BIOLASE, INC.
To: SWK FUNDING LLC, AS AGENT
Reel/Frame 047588/0192 →
RELEASE OF SECURITY INTEREST Recorded Nov 10, 2018
From: WESTERN ALLIANCE BANK
To: BIOLASE, INC.
Reel/Frame 048101/0027 →
SECURITY INTEREST Recorded Mar 7, 2018
From: BIOLASE, INC.
To: WESTERN ALLIANCE BANK
Reel/Frame 045514/0540 →
CHANGE OF NAME Recorded Nov 20, 2012
From: BIOLASE TECHNOLOGY, INC.
To: BIOLASE, INC.
Reel/Frame 029328/0096 →
RELEASE OF SECURITY INTEREST Recorded May 9, 2012
From: HENRY SCHEIN, INC.
To: BIOLASE TECHNOLOGY, INC.; BL ACQUISTION CORP.; BL ACQUISITION II INC.
Reel/Frame 028184/0218 →
SECURITY AGREEMENT PAYOFF Recorded May 16, 2011
From: MIDCAP FINANCIAL, LLC, AGENT AND AS LENDER
To: BIOLASE TECHNOLOGY, INC.
Reel/Frame 026285/0666 →
SECURITY AGREEMENT Recorded Sep 30, 2010
From: BIOLASE TECHNOLOGY, INC.; BL ACQUISITION CORP.; BL ACQUISITION II INC.
To: HENRY SCHEIN, INC.
Reel/Frame 025066/0488 →
SECURITY AGREEMENT Recorded Aug 28, 2010
From: BIOLASE TECHNOLOGY, INC.
To: MIDCAP FINANCIAL, LLC, AS AGENT AND AS A LENDER
Reel/Frame 024900/0550 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 3, 2008
From: JONES, JEFFREY W.; VAN VALEN, MARCIA ANGELA
To: BIOLASE TECHNOLOGY, INC.
Reel/Frame 021779/0233 →